You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復旦張江(01349.HK):奧貝膽酸片治療膽管炎臨牀試驗完成首例入組
復旦張江(01349.HK)宣佈,附屬公司泰州復旦張江藥業研發的奧貝膽酸片(規格:5mg、10mg),用於治療原發性膽汁性膽管炎(PBC)臨牀試驗於近日成功完成首例受試者入組。 公司表示,該藥物已完成與原研藥的人體生物等效性研究,並於今年4月獲得藥物臨牀試驗申請受理通知書,正式開展小規模驗證性橋接臨牀研究,旨在評價該藥物治療中國原發性膽汁性膽管炎患者的有效性和安全性,該藥物研究已於近日完成首例受試者入組,待本臨牀試驗完成後,根據相關法律法規,可提交上市申請。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account